Swiss Healthtech Startup Aeon Secures €8.2M In Seed Round

The funding round was led by VC firm Concentric, with support from Calm/Storm Ventures, GoHub Ventures, Kadmos Capital, and EWOR. Swiss angel investor Daniel Gutenberg—known for backing 12 unicorns like Airbnb, Facebook, and SumUp—also joined the round.

Unlike most health apps that use basic data from wearables or simple tests, Aeon combines full-body MRI scans, advanced blood biomarkers, and genetic data—all in a 60-minute check-up.

Read Also - Atmen Funding News -Germany Based Regtech Atmen Secures €5M Seed Funding

This approach helps detect and predict over 500 diseases and health risks, with results reviewed by certified doctors and discussed directly with a radiologist.

So far, Aeon has achieved a 0% false positive rate in clinical follow-ups—an important edge in a field often affected by overdiagnosis and unnecessary treatments.

Aeon uses AI in three key ways to improve early detection and prevention. First, it automates imaging analysis to spot and measure issues on MRI scans, making clinical evaluations faster and more consistent. Second, it cross-checks MRI, blood, and genetic data to reduce false positives and make the results more meaningful. Lastly, it builds a personalized risk profile for each user, predicting the chances of over 500 conditions and helping doctors focus on prevention.

Since its launch in 2024, Aeon has already identified early-stage cancers, aneurysms, Alzheimer’s, and other serious conditions—often in people with no symptoms. In one case, a 56-year-old man was found to have undiagnosed kidney cancer during a single scan, leading to life-saving surgery.

Aeon is the first health platform to offer full-body check-ups that are eligible for reimbursement by health insurers. It has already partnered with major Swiss providers like KPT. Depending on the plan, customers can get up to 80% of the cost back—making proactive healthcare more affordable and accessible.

The company was founded by CEO Tim Seithe, who previously built and sold Tillhub to Unzer (owned by KKR), and CPO Samuel Frey, a product expert who led a successful turnaround at diagnostics scale-up Platomics. They are supported by Dr. Andreas Lemke, a top MRI physicist in Europe and founder of Mediaire, known for its AI-based brain imaging tools.

“We’re redefining preventive care by shifting it from reactive checks to proactive, personalised health management. Our approach goes beyond early disease detection — we’re tackling one of preventive medicine’s biggest challenges: false positives,” said Tim Seithe, Aeon’s founder and CEO.

“Every customer receives a tailored risk profile, along with a clear, medically grounded plan to monitor and reduce their health risks over time.”

“Aeon is not just another testing solution. In our view, many consumer health products on the market today deliver questionable value,” said Alex Stroud, Principal at Concentric.

“Validated by insurers, Aeon is delivering the most medically robust preventive health product on the market. That rare combination of clinical rigour and commercial scalability is what makes this team so exciting.”

The new funding will help Aeon expand across Switzerland, Germany, and the UK, with plans to enter more international markets soon.

It will also boost partnerships with insurers and employers to make the service more accessible and affordable. Aeon will continue improving its AI-powered platform for faster and more accurate diagnoses and plans to open over 10 new locations in the coming months to grow its clinical network.

About Aeon

Founded in 2023, Aeon is the first preventive health platform that brings together multiple types of medical data to shift healthcare from treating illness to preventing it. By combining full-body MRI scans with blood tests, genetic data, and more, Aeon can spot diseases early and predict future health risks with high accuracy. Its use of AI improves diagnosis and helps lower costs, making advanced preventive care available to more people.